Results 191 to 200 of about 19,287 (223)
Some of the next articles are maybe not open access.
Postoperative hemorrhage secondary to acquired hemophilia A
JAAPA, 2020ABSTRACT Acquired hemophilia A in postoperative patients can cause major bleeding and an accurate diagnosis is required for effective treatment. Standard treatment is costly, difficult to obtain, and takes 4 to 6 weeks to be effective. This article describes a patient successfully treated with recombinant factor VIIa, porcine factor VIII ...
Zachary P, Asher +2 more
openaire +2 more sources
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2020
Acquired hemophilia A (AHA) is a bleeding disorder due to the autoantibody (inhibitor) production targeting blood coagulation factor VIII. It is characterized by a sudden onset, and it often causes extensive and severe bleeding in soft tissue. The incidence of AHA is 1.48 cases per 1 million individuals per year and is common among postpartum women and
openaire +1 more source
Acquired hemophilia A (AHA) is a bleeding disorder due to the autoantibody (inhibitor) production targeting blood coagulation factor VIII. It is characterized by a sudden onset, and it often causes extensive and severe bleeding in soft tissue. The incidence of AHA is 1.48 cases per 1 million individuals per year and is common among postpartum women and
openaire +1 more source
Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A
Seminars in Thrombosis and Hemostasis, 2012Acquired hemophilia A (AHA) is a rare, but often severe, bleeding disorder caused by autoantibodies against clotting factor VIII (FVIII). AHA occurs more frequently in the elderly and in association with several conditions, such as malignancies, autoimmune diseases, postpartum, or drug exposure; however, about half of the cases remain idiopathic.
Coppola, Antonio +5 more
openaire +3 more sources
Acquired hemophilia A associated with therapeutic cupping
The American Journal of Emergency Medicine, 2008Acquired hemophilia A is defined as the development of factor VIII inhibitors in a nonhemophilic patient. The inhibitors can develop in association with autoimmune disease, allergic drug reactions [1,2], malignancies [2], and pregnancy [3]. It is rare, but frequently complicated by severe bleeding and compartment syndrome [1,4].
Yi-Ming, Weng, Cheng-Ting, Hsiao
openaire +2 more sources
Acquired Circulating Anticoagulants in Hemophilia A
New England Journal of Medicine, 1969Abstract Factor VIII inhibitor was found in 16 of 77 patients (21 per cent) with severe hemophilia A. In 12 cases with marked inhibition, this became manifest after as few as 20, but no more than 90, accumulated days of exposure to transfusions, and usually before 10 years of age.
openaire +2 more sources
Innovative Therapies for Acquired Hemophilia A
Seminars in Thrombosis and HemostasisAbstractAcquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-threatening. AHA is due to autoantibodies against coagulation factor VIII. Disease onset may be idiopathic (approximately half of the cases) or triggered by autoimmune disorders, cancers, drugs, infections, or pregnancy. Besides treating the underlying disorder,
Massimo, Franchini, Daniele, Focosi
openaire +2 more sources
Acquired hemophilia in pediatrics: A systematic review
Pediatric Blood & Cancer, 2010Abstract Acquired hemophilia A is a rare but potentially life‐threatening hemorrhagic disorder caused by the development of autoantibodies directed mostly against coagulation factor VIII. Acquired hemophilia is frequently associated with several underlying conditions such as malignancy, autoimmune disorders, drug reactions, and ...
Franchini M., Zaffanello M., Lippi G.
openaire +2 more sources
[PREGNANCY RELATED ACQUIRED HEMOPHILIA A].
Harefuah, 2019Acquired hemophilia A is a rare disease. The incidence has been estimated to be 1.3-1.5 cases per 1 million persons per year. The etiology of acquired hemophilia A varies. It may develop in patients with autoimmune disorders, hematologic and solid cancers or in women during pregnancy or following childbirth.
Najib, Dally, Marat, Kashlikov
openaire +1 more source
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
New England Journal of Medicine, 2023Tadashi Matsushita
exaly
Bullous pemphigoid associated with acquired hemophilia A
Clinics in Dermatology, 2023Hanh, Nguyen +6 more
openaire +2 more sources